Carolin Schmidt, Robert Stöhr, Lora Dimitrova, Matthias W Beckmann, Matthias Rübner, Peter A Fasching, Carsten Denkert, Ulrich Lehmann, Claudia Vollbrecht, Florian Haller, Arndt Hartmann, Ramona Erber
In precision oncology, reliable testing of predictive molecular biomarkers is the prerequisite for optimal patient treatment. Interlaboratory comparisons are a crucial tool to verify diagnostic performance and reproducibility of one's approach. Here, we describe the design and results of the first recurrent, internationally performed PIK3CA Breast Cancer Tissue external quality assessment (EQA), which was organized by German Quality in Pathology (QuIP) GmbH and started in 2021. After the internal pretesting phase performed by the (lead) panel institutes, in both 2021 and 2022, each EQA test set comprised n=10 tissue samples of hormone receptor-positive, human epidermal growth factor receptor 2-negative invasive breast cancer (IBC) that had to be analyzed and reported by the participants...
April 30, 2024: Journal of Molecular Diagnostics: JMD